Biography
Michael Campbell, Ph.D. received his doctoral degree in Cancer Biology from Stanford University where he remained as a postdoctoral fellow in Oncology. Dr. Campbell was appointed Assistant Professor of Surgery at Stanford University in 1992. He joined the UCSF faculty as Assistant Professor of Surgery in 1997.
Dr. Campbell's areas of interest in research include breast neoplasms, cancer vaccines, immunotherapy, immunologic adjuvants, immunologic and biological factors, gene therapy, immunology, and breast cancer.
Education
Education
- 1978-82, University of Puget Sound, B.S., Biology
- 1978-82, University of Puget Sound, B.S., Mathematics
- 1983-87, Stanford University, Ph.D., Cancer Biology
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 59
- Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.| | PubMed
- Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.| | PubMed
- Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.| | PubMed
- Tumor microenvironmental determinants of high-risk DCIS progression.| | PubMed
- Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.| | PubMed
- Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.| | PubMed
- B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.| | PubMed
- Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards.| | PubMed
- Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.| | PubMed
- Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19.| | PubMed